Identification of Fyn as the binding partner for the WASP N-terminal domain in T cells

International Immunology

Volumn 23, Issue 8, 2011, Pages 493-502

  Sato, Mitsuru ^a   Sawahata, Ryoko ^a   Takenouchi, Takato ^a   Kitani, Hiroshi ^a  

^a NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

Author keywords

Fyn; IL 2 production; TCR signaling; WASP; WIP

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 2; PROTEIN KINASE FYN; TYROSINE; WISKOTT ALDRICH SYNDROME PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; TRANSGENIC MOUSE; WISKOTT ALDRICH SYNDROME;

EID: 79960734724     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr042     Document Type: Article

References (40)

1. Ochs, H. D., Slichter, S. J., Harker, L. A., Von Behrens, W. E., Clark, R. A. and Wedgwood, R. J. 1980. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 55:243.
2. Remold-O'Donnell, E., Rosen, F. S. and Kenney, D. M. 1996. Defects in Wiskott-Aldrich syndrome blood cells. Blood 87:2621.
3. Snapper, S. B., Rosen, F. S., Mizoguchi, E. et al. 1998. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9:81.
4. Zhang, J., Shehabeldin, A., da Cruz, L. A. et al. 1999. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J. Exp. Med. 190:1329.
5. Molina, I. J., Sancho, J., Terhorst, C., Rosen, F. S. and Remold-O'Donnell, E. 1993. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J. Immunol. 151:4383.
6. Symons, M., Derry, J. M., Karlak, B. et al. 1996. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell 84:723.
7. Banin, S., Truong, O., Katz, D. R., Waterfield, M. D., Brickell, P. M. and Gout, I. 1996. Wiskott-Aldrich syndrome protein (WASp) is a binding partner for c-Src family protein-tyrosine kinases. Curr. Biol. 6:981.
8. Bunnell, S. C., Henry, P. A., Kolluri, R., Kirchhausen, T., Rickles, R.J. and Berg, L. J. 1996. Identification of Itk/Tsk Src homology 3 domain ligands. J. Biol. Chem. 271:25646.
9. Cory, G. O., MacCarthy-Morrogh, L., Banin, S. et al. 1996. Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways. J. Immunol. 157:3791.
10. Rivero-Lezcano, O. M., Marcilla, A., Sameshima, J. H. and Robbins, K. C. 1995. Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains. Mol. Cell. Biol. 15:5725.
11. She, H. Y., Rockow, S., Tang, J. et al. 1997. Wiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and the epidermal growth factor receptor in living cells. Mol. Biol. Cell. 8:1709.
12. Higgs, H. N. and Pollard, T. D. 2000. Activation by Cdc42 and PIP(2) of Wiskott-Aldrich syndrome protein (WASp) stimulates actin nucleation by Arp2/3 complex. J. Cell Biol. 150:1311.
13. Blanchoin, L., Amann, K. J., Higgs, H. N., Marchand, J. B., Kaiser, D. A. and Pollard, T. D. 2000. Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. Nature 404:1007.
14. Zhu, Q., Watanabe, C., Liu, T. et al. 1997. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 90:2680.
15. Sato, M., Tsuji, N. M., Gotoh, H. et al. 2001. Overexpression of the Wiskott-Aldrich syndrome protein N-terminal domain in transgenic mice inhibits T cell proliferative responses via TCR signaling without affecting cytoskeletal rearrangements. J. Immunol. 167:4701.
16. Sato, M., Iwaya, R., Ogihara, K. et al. 2005. Intrabodies against the EVH1 domain of Wiskott-Aldrich syndrome protein inhibit T cell receptor signaling in transgenic mice T cells. FEBS J. 272:6131.
17. lck. EMBO J. 14:3403.
18. Takemoto, Y., Sato, M., Furuta, M. and Hashimoto, Y. 1996. Distinct binding patterns of HS1 to the Src SH2 and SH3 domains reflect possible mechanisms of recruitment and activation of downstream molecules. Int. Immunol. 8:1699.
19. Takemoto, Y., Sato, M., Furuta, M. and Hashimoto, Y. 1997. Expression plasmid vectors with convenient subcloning sites in kgt11 that efficiently produce detectable tagged proteins. DNA Cell Biol. 16:893.
20. Takemoto, Y., Furuta, M., Sato, M., Kubo, M. and Hashimoto, Y. 1999. Isolation and characterization of a novel HS1 SH3 domain binding protein, HS1BP3. Int. Immunol. 11:1957.
21. Dong, C., Davis, R. J. and Flavell, R. A. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20:55.
22. Jain, J., Loh, C. and Rao, A. 1995. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:333.
23. Rao, A., Luo, C. and Hogan, P. G. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707.
24. Hashimoto, Y. and Blank, K. J. 1990. T cell receptor genes and T cell development in virus-transformed early T cell lines. J. Immunol. 144:1518.
25. Ramesh, N., Anton, I. M., Hartwig, J. H. and Geha, R. S. 1997. WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells. Proc. Natl Acad. Sci. USA. 94:14671.
26. Pawson, T. and Gish, G. D. 1992. SH2 and SH3 domains: from structure to function. Cell 71:359.
27. Songyang, Z., Shoelson, S. E., Chaudhuri, M. et al. 1993. SH2 domains recognize specific phosphopeptide sequences. Cell 72:767.
28. Ren, R., Mayer, B. J., Cicchetti, P. and Baltimore, D. 1993. Identification of a ten-amino acid proline-rich SH3 binding site. Science 259:1157.
29. Zamoyska, R., Basson, A., Filby, A., Legname, G., Lovatt, M. and Seddon, B. 2003. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol. Rev. 191:107.
30. Banin, S., Gout, I. and Brickell, P. 1999. Interaction between Wiskott-Aldrich Syndrome protein (WASP) and the Fyn proteintyrosine kinase. Mol. Biol. Rep. 26:173.
31. Badour, K., Zhang, J., Shi, F., Leng, Y., Collins, M. and Siminovitch, K. A. 2004. Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J. Exp. Med. 199:99.
32. Sasahara, Y., Rachid, R., Byrne, M. J. et al. 2002. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol. Cell. 10:1269.
33. de la Fuente, M. A., Sasahara, Y., Calamito, M. et al. 2007. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc. Natl Acad. Sci. USA. 104:926.
34. Winslow, M. M., Neilson, J. R. and Crabtree, G. R. 2003. Calcium signalling in lymphocytes. Curr. Opin. Immunol. 15:299.
35. Martinez-Martinez, S. and Redondo, J. M. 2004. Inhibitors of the calcineurin/NFAT pathway. Curr. Med. Chem. 11:997.
36. Aubareda, A., Mulero, M. C. and Perez-Riba, M. 2006. Functional characterization of the calcipressin 1 motif that suppresses calcineurin-mediated NFAT-dependent cytokine gene expression in human T cells. Cell Signal. 18:1430.
37. Emmel, E. A., Verweij, C. L., Durand, D. B. et al. 1989. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246:1617.
38. Fruman, D. A., Klee, C. B., Bierer, B. E. and Burakoff, S. J. 1992. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl Acad. Sci. USA. 89:3686.
39. Bechstein, W. O. 2000. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int. 13:313.
40. Olyaei, A. J., de Mattos, A. M. and Bennett, W. M. 2001. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care. 7:384.